Medicare Enrolled
Dr. Wasif Shirazi, M.D.
Hematology & Oncology · Tinley Park, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shirazi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shirazi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shirazi
Dr. Wasif Shirazi is a hematology & oncology specialist in Tinley Park, IL, with 20 years of NPI registration. Based on federal Medicare data, Dr. Shirazi performed 251,197 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Shirazi received a total of $20,424 from 97 pharmaceutical and/or device companies across 1014 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shirazi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 1% volume in IL
$20,424 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗251,197
Medicare services
Top 1% in IL for hematology & oncology
Not available
Unique patients (not deduplicated)
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
87,390 | $2 | $21 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
45,000 | $1 | $5 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
24,900 | $0 | $7 |
| Pembrolizumab injection (Keytruda) | 21,000 | $43 | $146 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
19,500 | $0 | $36 |
| Nivolumab injection (Opdivo) | 17,480 | $24 | $81 |
| Denosumab injection (Prolia/Xgeva) | 6,780 | $19 | $71 |
| Paclitaxel chemotherapy injection | 3,501 | $0 | $5 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,474 | $0 | $3 |
| Rituximab-pvvr biosimilar injection, 10 mg An injection of rituximab-pvvr, a biosimilar medication, administered in a 10 mg dose. |
3,158 | $23 | $194 |
| Injection, atropine sulfate, 0.01 mg | 2,840 | $0 | $2 |
| Injection, leucovorin calcium, per 50 mg | 2,709 | $3 | $54 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,460 | $1 | $122 |
| Iron infusion (Monoferric) | 1,500 | $16 | $78 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,465 | $2 | $14 |
| Injection, granisetron hydrochloride, 100 mcg | 960 | $0 | $25 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
797 | $13 | $105 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
765 | $69 | $270 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
626 | $98 | $399 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
619 | $12 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
580 | $108 | $686 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
488 | $2 | $300 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
382 | $24 | $152 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
348 | $98 | $375 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
220 | $54 | $334 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
219 | $141 | $528 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
197 | $23 | $156 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
186 | $1 | $7 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
161 | $17 | $97 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
161 | $56 | $205 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
133 | $143 | $738 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
131 | $53 | $304 |
| New patient office visit, complex (60-74 min) | 119 | $177 | $760 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
116 | $7 | $462 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
101 | $46 | $281 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
99 | $212 | $986 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
96 | $1 | $8 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
90 | $66 | $268 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
81 | $16 | $91 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
80 | $30 | $240 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
67 | $1,301 | $4,120 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 64 | $400 | $638 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
38 | $1 | $19 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
33 | $19 | $111 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
30 | $27 | $141 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
20 | $25 | $249 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
18 | $2 | $19 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
15 | $11 | $73 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
19.1% high complexity
79.9% medium
1.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$20,424
Total received (2018-2024)
Avg $2,918/year across 7 years
Top 20% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
97
Companies
1,014
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,929
2023
$4,181
2022
$2,671
2021
$2,627
2020
$1,870
2019
$2,840
2018
$2,307
Payments by company (2024)
PFIZER INC.
$274
Gilead Sciences, Inc.
$255
Alexion Pharmaceuticals, Inc.
$218
BeiGene USA, Inc.
$188
Lilly USA, LLC
$176
E.R. Squibb & Sons, L.L.C.
$166
Astellas Pharma US Inc
$165
Genentech USA, Inc.
$157
Janssen Biotech, Inc.
$156
AstraZeneca Pharmaceuticals LP
$155
Novartis Pharmaceuticals Corporation
$154
Regeneron Healthcare Solutions, Inc.
$132
Exelixis Inc.
$120
Adaptive Biotechnologies Corporation
$110
GENZYME CORPORATION
$110
Merck Sharp & Dohme LLC
$99
GlaxoSmithKline, LLC.
$95
SEAGEN INC.
$95
Eisai Inc.
$92
ABBVIE INC.
$90
Bayer Healthcare Pharmaceuticals Inc.
$70
Ipsen Biopharmaceuticals, Inc
$66
Daiichi Sankyo Inc.
$60
Takeda Pharmaceuticals U.S.A., Inc.
$58
Tempus AI, Inc
$53
EMD Serono, Inc.
$53
SERVIER PHARMACEUTICALS LLC
$41
SpringWorks Therapeutics, Inc.
$40
TerSera Therapeutics LLC
$38
ARRAY BIOPHARMA INC
$37
Blueprint Medicines Corporation
$37
Aveo Pharmaceuticals, Inc.
$31
Incyte Corporation
$31
JAZZ PHARMACEUTICALS INC.
$29
Myriad Genetic Laboratories, Inc.
$29
Genmab U.S., Inc.
$28
Amneal Pharmaceuticals LLC
$26
Sumitomo Pharma America, Inc.
$26
Mirati Therapeutics, Inc.
$25
Immunocore Limited
$24
RECORDATI_RARE_DISEASES_INC.
$24
Kite Pharma, Inc.
$21
Celgene Corporation
$20
ADC Therapeutics America, Inc.
$19
TAIHO ONCOLOGY, INC.
$19
Amgen Inc.
$18
Top 3 companies account for 19.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,429
E.R. Squibb & Sons, L.L.C.
$1,349
Janssen Biotech, Inc.
$1,229
Genentech USA, Inc.
$950
Merck Sharp & Dohme Corporation
$929
PFIZER INC.
$903
Novartis Pharmaceuticals Corporation
$895
Amgen Inc.
$784
Incyte Corporation
$578
Lilly USA, LLC
$526
Merck Sharp & Dohme LLC
$516
Astellas Pharma US Inc
$469
Takeda Pharmaceuticals U.S.A., Inc.
$463
Gilead Sciences, Inc.
$449
Seagen Inc.
$430
Exelixis Inc.
$390
GENZYME CORPORATION
$374
Bayer HealthCare Pharmaceuticals Inc.
$350
Pharmacyclics LLC, An AbbVie Company
$341
Celgene Corporation
$336
BeiGene USA, Inc.
$317
Alexion Pharmaceuticals, Inc.
$307
GlaxoSmithKline, LLC.
$302
Regeneron Healthcare Solutions, Inc.
$293
Daiichi Sankyo Inc.
$268
EMD Serono, Inc.
$267
Janssen Pharmaceuticals, Inc
$242
Eisai Inc.
$226
Puma Biotechnology, Inc.
$196
AbbVie Inc.
$174
Rigel Pharmaceuticals, Inc.
$159
TESARO, Inc.
$156
Kite Pharma, Inc.
$156
Myriad Genetic Laboratories, Inc.
$153
Janssen Scientific Affairs, LLC
$144
AbbVie, Inc.
$144
Ipsen Biopharmaceuticals, Inc
$141
Dova Pharmaceuticals
$141
JAZZ PHARMACEUTICALS INC.
$136
Verastem, Inc.
$133
Adaptive Biotechnologies Corporation
$131
MorphoSys, US Inc.
$128
Karyopharm Therapeutics Inc.
$125
Foundation Medicine, Inc.
$121
ABBVIE INC.
$109
Bayer Healthcare Pharmaceuticals Inc.
$106
Seattle Genetics, Inc.
$105
SEAGEN INC.
$95
Pharmacyclics LLC, an AbbVie Company
$94
ARRAY BIOPHARMA INC
$92
Myovant Sciences Inc.
$83
TerSera Therapeutics LLC
$76
SANOFI-AVENTIS U.S. LLC
$68
G1 Therapeutics, Inc.
$64
Mirati Therapeutics, Inc.
$64
Aveo Pharmaceuticals, Inc.
$55
Tempus AI, Inc
$53
Genmab U.S., Inc.
$53
ADC Therapeutics America, Inc.
$52
Coherus Biosciences Inc.
$50
Progenics Pharmaceuticals, Inc.
$49
Blueprint Medicines Corporation
$48
CTI BioPharma Corp.
$48
RECORDATI_RARE_DISEASES_INC.
$46
SERVIER PHARMACEUTICALS LLC
$41
Dendreon Pharmaceuticals LLC
$41
Boehringer Ingelheim Pharmaceuticals, Inc.
$40
SpringWorks Therapeutics, Inc.
$40
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$39
Taiho Oncology, Inc.
$34
Aurobindo Pharma USA, Inc.
$29
Amneal Pharmaceuticals LLC
$26
Sumitomo Pharma America, Inc.
$26
Teva Pharmaceuticals USA, Inc.
$26
Jazz Pharmaceuticals Inc.
$25
Deciphera Pharmaceuticals Inc.
$24
Immunocore Limited
$24
Nestle HealthCare Nutrition Inc.
$24
Pharmacosmos Therapeutics Inc.
$23
Synergy Pharmaceuticals Inc
$23
Sobi, Inc
$23
Acrotech Biopharma LLC
$21
Immunomedics, Inc.
$20
Epizyme, Inc.,
$20
TOLMAR Pharmaceuticals, Inc.
$20
TAIHO ONCOLOGY, INC.
$19
Shire North American Group Inc
$17
Clovis Oncology, Inc.
$17
Tactile Systems Technology Inc
$16
Kyowa Kirin, Inc.
$15
AVEO Pharmaceuticals, Inc.
$15
Global Blood Therapeutics, Inc.
$15
Array BioPharma Inc.
$15
EISAI INC.
$14
GE HealthCare
$13
Blue Earth Diagnostics Limited
$12
Fortovia Therapeutics, Inc.
$10
Top 3 companies account for 19.6% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALUNBRIG · AVASTIN · AYVAKIT · Alecensa · Aliqopa · Asparlas · Avastin · Axumin · BAVENCIO · BENDEKA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Beleodaq · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CHANTIX · COSELA · CREON · CYRAMZA · Cabometyx · Columvi · Copiktra · DAKLINZA · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Enhertu · Entyvio · Epkinly · Erleada · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GATTEX · GAVRETO · GAZYVA · GILOTRIF · HEMADY · IBRANCE · ICLUSIG · IMBRUVICA · IMDELLTRA (AMG 757) · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Itovebi · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MYRISK · Marqibo · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROSTATE CANCER - DISEASE · PROVENGE · PYLARIFY · Padcev · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RECOTHROM · RYBREVANT · Rezlidhia · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYLVANT · Somatuline Depot · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TEPMETKO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · Trulance · UCERIS TABLETS · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
239
County median income
$81,797
Nearest hospital to ZIP centroid (approximate)
PALOS COMMUNITY HOSPITAL
7.1 mi
7.1 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shirazi is a mixed practice specialist, with above-average Medicare volume (top 1% in IL), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shirazi experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Shirazi performed 87,390 darbepoetin injection (aranesp) for anemia services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Shirazi receive payments from pharmaceutical companies?
Yes. Dr. Shirazi received a total of $20,424 from 97 companies across 1,014 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shirazi's costs compare to other hematology & oncology specialists in Tinley Park?
Dr. Shirazi's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shirazi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Tinley Park
Browse hematology & oncology specialists in Tinley Park ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology